Primary Lab Test for Tigecycline Effectiveness
Tigecycline, an intravenous glycylcycline antibiotic used for complicated infections like skin/soft tissue or intra-abdominal infections, has its effectiveness measured mainly by minimum inhibitory concentration (MIC) tests. These determine the lowest tigecycline concentration that inhibits visible bacterial growth after 18-24 hours of incubation.[1]
MIC is performed using:
- Broth microdilution (FDA/CLSI reference method): Serial dilutions in cation-adjusted Mueller-Hinton broth assess susceptibility for pathogens like Acinetobacter baumannii, Enterobacteriaceae, and Staphylococcus aureus. Breakpoints are ≤2 mg/L (susceptible), 4 mg/L (intermediate), ≥8 mg/L (resistant).[2]
- Disk diffusion (Kirby-Bauer): Less precise for tigecycline; zone diameters ≥19 mm indicate susceptibility, but MIC is preferred due to variability.[3]
How MIC Testing Works for Tigecycline
Bacteria from clinical samples (e.g., blood, wound swabs) are isolated and grown. Tigecycline is diluted across wells; growth absence in the lowest concentration well signals susceptibility. Results guide dosing (50 mg IV q12h after 100 mg load). High MICs predict treatment failure, especially in multidrug-resistant cases.[1][2]
Monitoring Treatment Response Beyond Susceptibility
Once therapy starts, effectiveness is tracked via:
- Serial cultures: Repeat blood, sputum, or tissue cultures to confirm bacterial clearance (negative cultures indicate response).[4]
- Pharmacokinetic/pharmacodynamic (PK/PD) tests: Serum tigecycline levels (target AUC/MIC >12-24 for efficacy) via HPLC/MS, though not routine outside research or critical cases.[5]
- Biomarkers: Procalcitonin or CRP levels drop with successful treatment, but these are nonspecific.[4]
No single blood test directly measures tigecycline levels in practice; focus remains on pathogen-specific MIC and clinical resolution.
Common Pathogens and Tigecycline MIC Data
| Pathogen Group | Typical MIC90 (mg/L) | Notes |
|---------------|----------------------|-------|
| E. coli, Klebsiella | 1-2 | Good activity unless tet(A) efflux pumps present |
| A. baumannii | 2-4 | Variable; rising resistance |
| S. aureus (MRSA) | ≤0.5 | Reliable unless efflux-mediated |
| Enterococcus spp. | 1-4 | Effective against VRE |
Resistance emerges via efflux pumps or ribosomal protection; retest isolates if failure suspected.[2][3]
Limitations and When Tests Fail
Tigecycline's bacteriostatic action (not bactericidal) means MIC doesn't always predict clinical cure—high-inoculum effects can elevate MICs in vivo. Avoid for bacteremia or pneumonia per FDA warnings due to poor outcomes despite low MICs.[6] Consult CLSI M100 tables for updated breakpoints.
Sources
[1] StatPearls: Tigecycline
[2] CLSI M100, 34th ed.
[3] Tygacil (tigecycline) Prescribing Information
[4] IDSA Guidelines: Complicated Infections
[5] PK/PD of Tigecycline Review
[6] FDA Safety Communication: Tigecycline